| Biomarker ID | 96 |
| PMID | 15870707 |
| Year | 2005 |
| Biomarker | E-cadherin |
| Biomarker Basis | Concentration Based (μg/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Iincreased risk of late biochemical failure with high expression |
| Odds Ratio/Hazard Ratio/Relative Risk | RR: 55.1 |
| Effect on Pathways | Pathways include: 1. Integrin cell surface interactions 2. Nuclear beta-catenin signaling and target gene transcription regulation 3. Cell junction organization 4. Adherens junction cell adhesion 5. Neural crest differentiation |
| Experiment | Biochemical Faliure Vs No Biochemical Faliure |
| Type of Biomarker | Prognostic |
| Cohort | 109 patients with localised prostate cancer (Loc PCA) and no biochemical failure, and 21 cases with localised PCA and biochemical failure after surgery. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Enzyme Immunoassay (EIA) |
| Clinical | No |
| Remarks | cutoff expression level 7.9 μg/l |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CDH1 |